There's no shortage of noise in the 340B space right now. New rules proposed, old rules challenged, political winds shifting. But while the policy conversation cycles, drug costs keep climbing—and the patients in your waiting room don't pause.
U.S. retail prescription drug spending is projected to reach roughly $678 billion by 2030, up from $495 billion in 2024—a 37% increase over six years.*
The pressure isn't coming from volume—that's only growing 1–2% a year. It's mix shift. Specialty therapies, GLP-1s, and 50–55 new drug launches annually are pushing cost-per-script higher even as total fills stay flat.
For health centers managing tight margins, that gap is where the financial stress lives.
The organizations doing this well right now share a pattern: they’re building operational infrastructure that works regardless of what happens in Washington. Here’s where that starts:
Split your pharmacy forecast into three buckets.
Traditional retail, specialty, and medical benefit drugs each behave differently. One line item hides the real story.
Make your GLP-1 strategy explicit.
CMS flags anti-obesity uptake as a direct spending driver through 2027—but price competition is only half the story.
Coverage is shifting at the same time: Medicaid is increasingly limiting GLP-1s to non-weight-loss indications, while new ones like sleep apnea and alcohol addiction are opening up. The same drug could be more or less accessible depending on diagnosis.
If your formulary committee is treating GLP-1s like any other class, your forecast may not reflect what's actually coming.
Build IRA timing into your planning.
The second round of Medicare price negotiations takes effect in 2027. For Medicare-heavy populations, that’s when you’ll feel it—but not overnight.
Plan for 50+ new drug launches per year.
That pace means formulary review and contracting can't be a quarterly exercise—it needs to be continuous.
Know where your 340B dollars go, across all three buckets.
Specialty drug spending typically grows 8–12% annually—well above overall trend.** Every eligible script you don’t capture is cash flow that could have funded another provider or kept your doors open for the patients who depend on you.
That’s the signal worth following. And it’s the work NuvemRx does alongside 800+ covered entities every day—plugging the leaks so the dollars flow back where they belong.
* CMS National Health Expenditure projections, applying stated growth rates of ~5.6% for 2026–27 and ~4.7% for 2028–30.
** Planning heuristic consistent with IQVIA net medicine spending outlook, 2024; validate against your own specialty mix.